Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493703 | 0.86 | GAA (0.35) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL448758 | 0.77 | GAA (0.44) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28986081 | 0.76 | GAA (0.43) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL28264866 | 0.76 | GAA (0.43) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL19679 | 0.75 | — | — | |
| SCHEMBL29144954 | 0.70 | GAA (0.54) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL123812 | 0.70 | GAA (0.54) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29408147 | 0.70 | GAA (0.54) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1451010 | 0.70 | DRD2 (0.50) | — | |
| SCHEMBL3041192 | 0.70 | GAA (0.41) | GAAMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233345-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | claimed |
| EP-3180006-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-21 | — | — | EP | claimed |
| WO-2016023885-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | WO | claimed |
| US-9126998-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | Bayer Pharma AG (DE) | 2015-09-08 | — | — | US | claimed |
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | claimed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | claimed |
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | claimed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | claimed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | claimed |
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | claimed |
| EP-1599174-A2 | NOVEL COMPOUNDS | Replidyne, Inc. (US) | 2005-11-30 | — | — | EP | claimed |
| CN-1694870-A | Acetyl 2-hydroxy-1, 3-diaminoalkanes | PHARMACIA & UPJOHN CO LLC (US) | 2005-11-09 | — | — | CN | claimed |
| US-6884802-B2 | 6-heteroarylphenanthridines | ALTANA PHARMA AG (DE) | 2005-04-26 | — | — | US | claimed |
| WO-2004069196-A2 | NOVEL COMPOUNDS | REPLIDYNE, INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-20040038979-A1 | Treating airway disorders such as asthma. | ALTANA PHARMA AG (DE) | 2004-02-26 | — | — | US | claimed |
| JP-2003500397-A | — | — | 2003-01-07 | — | — | JP | claimed |
| JP-2003500395-A | — | — | 2003-01-07 | — | — | JP | claimed |
| WO-2000071522-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS METHIONYL T-RNA SYNTHETASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-30 | — | — | WO | claimed |
| WO-2000071524-A1 | 2-NH-PYRIDONES AND PYRIMIDONES AS MRS INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-30 | — | — | WO | claimed |
| US-5294612-A | Hypotensive agents and cardiovascular disorders | STERLING WINTHROP INC. (US) | 1994-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128372-A1 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | GAA 2804/4885MEN1 2194/4885KMT2A 1080/4885 |
| US-20170233345-A1 | SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF | NQO2, SIRT5, BRD4 | GAA 615/4885MEN1 2611/4885KMT2A 684/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GAA 4177/4885MEN1 3744/4885KMT2A 4629/4885 |
| US-20040038979-A1 | Treating airway disorders such as asthma. | PTGER4, PDE4B, PDE4A | GAA 4138/4885MEN1 4313/4885KMT2A 3933/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GAA 4072/4885MEN1 3677/4885KMT2A 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.